O4‐01‐08: Donepezil high‐dose extended‐release tablets provide greater benefit to moderate‐to‐severe Alzheimer patients already treated with donepezil immediate‐release tablets

outcome measure (CSF Ab42) at 9 months compared to placebo (n1⁄4 49) (p 1⁄4 0.895). However, APOE4 allele, baseline cholesterol levels, and baseline CSF biomarker levels interacted significantly with treatment to impact primary and secondary outcome measures. The results of these interactions will be presented. Conclusions: In middle-aged adults with parental history of AD, the effect of simvastatin on CSF, MRI perfusion, and cognitive AD biomarkers may be significantly influenced by underlying risk profile. Understanding how these factors influence response to therapy may help guide future trials assessing the role of statins in AD prevention.